SALT LAKE CITY--(BUSINESS WIRE)--Clinical Innovations, one of the largest medical device companies exclusively focused on labor and delivery and the neonatal intensive care unit, today announced the official launch of the ebb Complete Tamponade System, which is an effective treatment for postpartum hemorrhage (PPH).
Postpartum hemorrhage is one of the leading causes of maternal mortality. As part of Clinical Innovations’ mission to improve the lives of mothers and their babies throughout the world, ebb allows for rapid, emergency deployment to significantly reduce or eliminate bleeding in up to 98 percent of patients.1
With its unique, malleable polyurethane material and patented dual-balloon design, ebb conforms to the patient’s anatomy and can help avoid hysterectomy, according to a large prospective study published in the American Journal of Obstetrics and Gynecology.
“Postpartum hemorrhage puts up to 200,000 mothers in the U.S. at risk every year and can be fatal in hours if untreated. The ebb Complete Tamponade System’s rapid-response design is an easy-to-deploy, cost-effective solution for improving patient outcomes associated with PPH,” said Dr. Ross McQuivey, chief medical officer for Clinical Innovations. “We’re committed to developing safe, reliable and innovative solutions to improve the lives of mothers and their babies, and we’re proud to have ebb return as a core part of our growing labor and delivery product portfolio.”
After receiving FDA clearance in January of 2016, Clinical Innovations conducted a successful limited release where ebb has been used in hospitals throughout the United States and Europe for the past year. “We have had great feedback on ebb and excellent clinical results for the treatment of PPH. We are excited to launch ebb so clinicians can utilize this critical device to save lives throughout the world,” said Jeff Bradford, vice president global marketing.
About Clinical Innovations
Clinical Innovations is one of the largest medical device companies exclusively focused on labor and delivery and the neonatal intensive care unit. Already a market leader in several categories with products such as the Koala® Intrauterine Pressure Catheter; Kiwi® Vacuum-Assisted Delivery System; ROM Plus® Rupture of Membranes Test; traxi® Panniculus Retractor, ClearView Uterine Manipulator and recently added babyLance Safety heel stick. Clinical Innovations is expanding its global presence while directly researching and developing state-of-the-art technologies and innovative medical devices that fulfill its mission of improving the lives of mothers and their babies throughout the world. Clinical Innovations is a Pritzker Group company. For more information, visit clinicalinnovations.com.
About Pritzker Group
Pritzker Group, led by Tony and J.B. Pritzker, has three principal investment teams: Private Capital, which acquires and operates leading North America-based companies; Venture Capital, which provides early-stage and growth venture funding to technology companies throughout the United States; and Asset Management, which partners with top-performing investment managers across global public markets.
Pritzker Group Private Capital acquires North America-based middle-market companies with leading positions in the manufactured products, services and healthcare sectors. The firm’s permanent, proprietary capital base allows for efficient decision making, broad flexibility with transaction structure and investment horizon, and alignment with management teams focused on creating long-term value. Pritzker Group brings significant resources, expertise and credibility in building businesses and is an ideal partner for entrepreneur- and family-owned companies. For more information, visit pritzkergroup.com.
1. Initial experience with a dual-balloon catheter for the management of postpartum hemorrhage. Dildy GA, Belfort MA, Adair D, et al. Am J Obstet Gynecol. 2014;210:136.e1-6.